Association of homocysteine with traditional and non-traditional risk factors in patients with atherosclerotic vascular disease

Medicinski Glasnik

Volumn 8, Issue 1, 2011, Pages 126-133

  Kiseljaković, Emina ^a   Valjevac, Amina ^a   Hasić, Sabaheta ^a   Nakaš Ićindić, Emina ^a   Džubur, Alen ^b   Jadrić, Radivoj ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^b UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

Atherosclerotic vascular disease; Homocysteine; Risk factors

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RISK FACTOR;

ATHEROSCLEROSIS; C-REACTIVE PROTEIN; FEMALE; HOMOCYSTEINE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; URIC ACID;

EID: 79551709176     PISSN: 18400132     EISSN: 18402445     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rundek T, Demarin V. Carotid intima-median thickness (IMT): A surrogate marker of atherosclerosis. Acta Clin Croat 2006; 45:45-51. (Pubitemid 43893320)
2. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004; 109(23 Suppl 1):III15-9.
3. Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol 1996; 27:978-90.
4. Harjai KJ. Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen. Ann Intern Med 1999; 131:376-386 (Pubitemid 29424632)
5. U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:474-82.
6. NACB LMPG Committee Members, Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, Grundy SM, Labarthe DR, Levy D, Rifai N, Wilson PW. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009; 55:378-84.
7. Selhub J. Homocysteine metabolism. Annu Rev Med 1999; 19:217-46. (Pubitemid 29380603)
8. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999; 10:891-900. (Pubitemid 29149541)
9. Lentz S.R. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005; 3:1646-54. (Pubitemid 41716550)
10. Thambyrajah J, Townend JN. Homocysteine and at herothrombosis - mechanisms for injury. Eur Heart J 2000; 21:967-74.
11. Aguilar B, Rojas JC, Callados MT. Metabolism of homocysteine and its relationship with cardiovascular disease. J Thromb Thromboly 2004; 18:75-87. (Pubitemid 40485113)
12. Kiseljaković E, Jadrić R, Hasić S, Skenderi F, Resić H, Winterhalter-Jadrić M. Polymorphism in methylentetra-hydrofolate reductase gene: important role in diseases. Bosn J Basic Med Sci 2008; 8:165-9.
13. Herrmann W, Herrmann M, Obeid R. Hyperhomo-cysteinemia: A critical review of old and new aspects. Curr Drug Metab 2007; 8:17-31. (Pubitemid 46043889)
14. Meiklejohn DJ, Vickers MA, Dijkhuisen R, Greaves M. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001; 32:57-62. (Pubitemid 32063824)
15. Valjevac A, Dzubur A, Nakas-Ićindić E, Hadzović- Dzuvo A, Zaćiragić A, Lepara O, Arslanagić A. Changes in serum homocysteine level follow two different trends in patients during early post myocardial infarction period. Bosn J Basic Med Sci 2009; 9:161-5.
16. Harjai HJ. New paradigms in preventive cardiology: unconventional coronary risk factors. The Ochsner Journal 2000; 2:209-17.
17. Lim TK, Lim E, Dwivedi G, Kooner J, Senior R. Normal value of carotid intima-media thickness - a surrogate marker of atherosclerosis: quantitative assessment by B-mode carotid ultrasound. J Am Soc Echocardiogr 2008; 21:112-6. (Pubitemid 351186886)
18. Murray CJ, Lopez AD.Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269-76. (Pubitemid 27192468)
19. Grundy SM, Cleeman Jl, Merz CN, for the Coordinating Committee of the National Cholesterol Education Program and Endorsed by the National Heart, Lung, and Blood lnstitute, Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation, and American Heart Association. lmplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel lll Guidelines. Circulation 2004;110:227-39.
20. Rassoul F, Richter V, Hentschel B, Geisel J, Herrmann W, Kuntze T. Plasma homocysteine levels & 677C - >T methylenetetrahydrofolate reductase gene polymorphism in patients with coronary artery disease of different severity. Indian J Med Res 2008;127:154-8. (Pubitemid 351936166)
21. Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem. 2003 ;36(6):431-41. (Pubitemid 37086702)
22. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, Zhou J, Maeda N, Krisans SK, Malinow MR, Austin RC. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001;107:1263-73. (Pubitemid 32494543)
23. Sadeghian S, Fallahi F, Salarifar M, Davoodi G, Mahmoodian M, Fallah N, Darvish S, Karimi A; Tehran Heart Center. Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. BMC Cardiovasc Disord 2006; 6:38.
24. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15:442-53. (Pubitemid 38140786)
25. Holven KB, Aukrust P, Retterstøl K, Otterdal K, Bjerkeli V, Ose L, Nenseter MS, Halvorsen B. The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects. J Nutr 2008;138:2070-5.
26. Chan SJ, Chang CN, Hsu JC, Lee XS and Shen CH. Homocysteine, Vitamin B6, and Lipid in Cardiovascular disease. Nutrition 2002; 18:595-8.
27. Malanovic N, Streith I, Wolinski H, Rechberger G, Kohlwein SD and Tehlivets O. Sadenosyl-L-homocysteine hydrolase, key enzyme of methylation metabolis, regulates phosphatidylcholine synthesis and triacilglycerol homeostasis in yeast: implication for homocysteine as a risk factor of atherosclerosis. J Biol Chem 2008; 283:23989-9.
28. Li H, Lewis A, Brodsky S, Rieger R, Iden C, Goligorsky MS. Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis? Circulation. 2002; 105:1037-43.
29. Qujeq D, Omran TS, Hosini L Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem. 2001; 34:97-101. (Pubitemid 32322699)
30. Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol 1997; 54:1276-82. (Pubitemid 27452243)
31. Motti C, Gnasso A, Bernardini S, Massoud R, Pastore A, Rampa P, Federici G, Cortese C. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine and other risk factors for vascular disease. Atherosclerosis. 1998; 139:377-83.
32. Malinow MR, Levenson J, Giral P, Nieto FJ, Razavian M, Segond P, Simon A. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995; 114:175-83.
33. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148:131-9.
34. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Curr Pharm Des 2005; 11:4145-51. (Pubitemid 41672464)
35. Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J 2004; 3:4.